PPARG and cancer: When evaluated for mutation, 77.7% of cancers had BRAF V600E; 8.8% showed RET/PTC rearrangements; 4.4% were positive for PAX8/PPAr gamma and 9.1% had RAS mutations (H- and K-, no NRAS mutations were found in our series).